Curcumin acts synergistically with fluconazole to sensitize a clinical isolate of Candida albicans showing a MDR phenotype

References

• Pfaller MA, Messer SA, Boyken L, . Caspafungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003; 41: 5729–5731.
   PubMed Web of Science ®Google Scholar
• Karkowska-Kuleta J, Rapala-Kozik M, Kozik A. Fungi pathogenic to humans: molecular bases of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. Acta Biochim Polon 2009; 55: 211–224.
   Google Scholar
• Pfaller MA, Lockhart SR, Pujol C, . Hospital specificity, region specificity, and fluconazole resistance of Candida albicans bloodstream isolates. J Clin Microb 1998; 36: 1518–1529.
   PubMed Web of Science ®Google Scholar
• Eggimann P, Garbino J, Pittet D. Management of Candida species infections in critically ill patients. Lancet Infect Dis 2003; 3: 772–785.
   PubMed Web of Science ®Google Scholar
• Olaechea PM, Palomar M, Leon-Gil C, . Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004; 23: 323–330.
   PubMedGoogle Scholar
• Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34: 857–863.
   PubMed Web of Science ®Google Scholar
• Leroy O, Gangneux JP, Montravers P, . Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med 2009; 37: 1612–1618.
   PubMed Web of Science ®Google Scholar
• Perfect JR, Casadevall A. Fungal molecular pathogenesis: what can it do and why do we need it? Heitman J, Molecular Principles of Fungal Pathogenesis. Washington, DC: ASM Press, 2006; 3–11.
   Google Scholar
• Mavor AL, Thewes S, Hube B. Systemic fungal infections caused by Candida species: epidemiology, infection process and virulence attributes. Curr Drug Targets 2005; 6: 863–874.
   PubMed Web of Science ®Google Scholar
• Guo XL, Leng P, Yang Y, Lou HX. Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fluconazole relating to the efflux pump. J Appl Microbiol 2008; 104: 831–838.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73–85.
   PubMed Web of Science ®Google Scholar
• Richardson K. The discovery and profile of fluconazole. J Chemother 1990; 2: 51–54.
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A, . Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006; 57: 384–410.
   PubMed Web of Science ®Google Scholar
• Perea S, Lopez-Ribot JL, Kirkpatrick WR, . Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strain displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676–2684.
   PubMed Web of Science ®Google Scholar
• White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. J Clin Microbiol 1998; 11: 382–402.
   Google Scholar
• Prasad R, Dewergifosse P, Goffeau A, Balzi E. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr Genet 1995; 27: 320–329.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Kuchler K, Ischer, F . Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378–2386.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Monod M, Billie J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997; 143: 405–416.
   PubMed Web of Science ®Google Scholar
• Morschhäuser, J. The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240–248.
   PubMed Web of Science ®Google Scholar
• Sharma M, Manoharlal R, Shukla S, . Curcumin modulates efflux mediated by yeast ABC multidrug transporters and is synergistic with antifungals. Antimicrob Agen Chem 2009; 53: 3256–3265
   PubMedGoogle Scholar
• Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agen 2007; 30: 107–108.
   Google Scholar
• Julie S, Jurenka MT. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev 2009; 14: 141–153.
   PubMedGoogle Scholar
• Rowe DL, Ozbay T, O'Regan RM, Nahta R. Modulation of the BRCA1 protein and induction of apoptosis in triple negative breast cancer cell lines by the polyphenolic compound curcumin. Breast Cancer 2009; 2: 61–75.
   Google Scholar
• Limtrakul P, Anuchapreeda S, Buddhasukh D. Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 2004; 4: 1–6.
   PubMedGoogle Scholar
• Govindarajan VS. Turmeric: chemistry, technology and quality. Crit Rev Food Sci Nutr 1990; 12: 199–301.
   Google Scholar
• Ammon HPT, Wahl MA. Pharmacology of Curcuma longa. Planta Med 1991; 57: 1–7.
   PubMed Web of Science ®Google Scholar
• Strimpakos AS, Sharma RA. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 2008; 10: 511–545.
   PubMed Web of Science ®Google Scholar
• Qureshi S, Shah AH, Ageel AM. Toxicity studies on Alpinia galanga and Curcuma longa. Planta Med 1992; 58: 124–127.
   PubMed Web of Science ®Google Scholar
• Shankar TN, Shantha NV, Ramesh HP, Murthy IA, Murthy VS. Toxicity studies on turmeric: acute toxicity studies in rats, guinea pigs and monkeys. Indian J Exp Biol 1980; 18: 73–75.
   PubMed Web of Science ®Google Scholar
• Braga-Silva LA, Santos ALS, Portela MB, Souto-Padron TCB, Araujo Soares RM. Effect of suramin on the human pathogen Candida albicans: implications on the fungal development and virulence. FEMS Immunol Med Microbiol 2007; 51: 399–406
   PubMedGoogle Scholar
• National Commitee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 2nd. Approved standard M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards 2002.
   Google Scholar
• Yamamoto S, Hiraga K, Abiko A, Hamanaka M, Oda K. A new function of isonitrile as an inhibitor of the Pdr5p multidrug ABC transporter in Saccharomyces cerevisiae. Biochem Biophys Res 2005; 330: 622–628.
   PubMedGoogle Scholar
• Orhan G, Bayram A, Zer Y. Synergy test by E test and checkerboard methods of antimicrobial combinations against Brucella melitensis. J Clin Microbiol 2005; 43: 140–143.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum ML. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18: 163–194.
   PubMed Web of Science ®Google Scholar
• Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
   PubMed Web of Science ®Google Scholar
• Maesaki SP, Marichal H, Vanden Bossche D, Sanglard D, Kohno S. Rhodamine 6G efflux for the detection of CDR1-overexpressing azole-resistant Candida albicans strains. J Antimicrob Chemother 1999; 44: 27–31.
   PubMedGoogle Scholar
• Nakamura K, Niimi M, Niimi K, . Functional expression of Candida albicans drug efflux pump Cdr1p in Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrobiol Agents Chemother 2001; 45: 3366–3374.
   PubMed Web of Science ®Google Scholar
• Gauthier C, Weber S, Alarco AM, . Functional similarities and differences between Candida albicans Cdr1p and Cdr2p transporters. Antimicrob Agents Chemother 2003; 47: 1543–1554.
   PubMed Web of Science ®Google Scholar
• Ivnitski-Steele I, Holmes AR, Lamping E, . Identification of Nile red as a fluorescent substrate of the Candida albicans ATP-binding cassette transporters Cdr1p and Cdr2p and the major facilitator superfamily transporter Mdr1p. Analyt Biochem 2009; 394: 87–91.
   PubMed Web of Science ®Google Scholar
• Gulsham K, Moye-Rowley WS. Multidrug resistance in fungi. Eucaryotic Cell 2007; 6: 1933–1942.
   PubMedGoogle Scholar
• Willocks L, Leen CL, Brettle RP, . Fluconazole resistance in AIDS patients. J Antimicrob Chemother 1991; 28: 937–939.
   PubMedGoogle Scholar
• Pinjon E, Moran GP, Coleman DC, Sullivan DJ. Azole susceptibility and resistance in Candida dubliniensis. Biochem Soc Trans 2005; 33: 1210–1214.
   PubMed Web of Science ®Google Scholar
• Ben-Yaacov RS, Knoller S, Caldwell GA, Becker JM, Koltin Y. Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene. Antimicrobiol Agents Chemother 1994; 38: 648–652.
   PubMedGoogle Scholar
• Fling ME, Kopf J, Tamarkin A, . Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol Gen Genet 1991; 227: 318–329.
   PubMedGoogle Scholar
• Franz R, Kelly SL, Lamb DC, . Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42: 3065–3072.
   PubMed Web of Science ®Google Scholar
• Franz R, Ruhnke M, Morschhauser J. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 1999; 42: 453–458.
   PubMedGoogle Scholar
• Lopez-Ribot JL, McAtee RK, Lee LN, . Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 1998; 42: 2932–2937.
   PubMed Web of Science ®Google Scholar
• Perea S, Lopez-Ribot JL, Kirkpatrick WR. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676–2684.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Kuchler K, Ischer F, . Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378–2386.
   PubMed Web of Science ®Google Scholar
• White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482–1487.
   PubMed Web of Science ®Google Scholar
• Wirsching S, Michel S, Morschhauser J. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol Microbiol 2000; 36: 856–865.
   PubMed Web of Science ®Google Scholar